VBI Vaccines Stock Price, News & Analysis (NASDAQ:VBIV)

$4.54 0.02 (0.44 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$4.52
Today's Range$4.42 - $4.66
52-Week Range$2.81 - $6.60
Volume125,634 shs
Average Volume154,940 shs
Market Capitalization$289.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines logoVBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.


Industry, Sector and Symbol:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:VBIV
  • CUSIP: N/A
  • Web: www.vbivaccines.com
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 1.03%
  • Quick Ratio: 0.97%
Sales & Book Value:
  • Annual Sales: $550,000.00
  • Price / Sales: 526.72
  • Book Value: $2.30 per share
  • Price / Book: 1.97
Profitability:
  • Trailing EPS: ($0.73)
  • Net Income: $-23,200,000.00
  • Net Margins: -4,463.06%
  • Return on Equity: -49.17%
  • Return on Assets: -37.55%
Misc:
  • Employees: 90
  • Outstanding Shares: 63,810,000
 

Frequently Asked Questions for VBI Vaccines (NASDAQ:VBIV)

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Where is VBI Vaccines' stock going? Where will VBI Vaccines' stock price be in 2017?

3 equities research analysts have issued 12-month target prices for VBI Vaccines' shares. Their forecasts range from $10.00 to $11.00. On average, they expect VBI Vaccines' stock price to reach $10.50 in the next year. View Analyst Ratings for VBI Vaccines.

Who are some of VBI Vaccines' key competitors?

Who owns VBI Vaccines stock?

VBI Vaccines' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Cambridge Investment Research Advisors Inc. (2.22%) and Russell Investments Group Ltd. (0.54%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Institutional Ownership Trends for VBI Vaccines.

Who bought VBI Vaccines stock? Who is buying VBI Vaccines stock?

VBI Vaccines' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Cambridge Investment Research Advisors Inc.. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Insider Buying and Selling for VBI Vaccines.

How do I buy VBI Vaccines stock?

Shares of VBI Vaccines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBI Vaccines stock can currently be purchased for approximately $4.54.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $289.67 million and generates $550,000.00 in revenue each year. The biopharmaceutical company earns $-23,200,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. VBI Vaccines employs 90 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for VBI Vaccines (NASDAQ:VBIV)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.50 (131.28% upside)

Consensus Price Target History for VBI Vaccines (NASDAQ:VBIV)

Price Target History for VBI Vaccines (NASDAQ:VBIV)

Analysts' Ratings History for VBI Vaccines (NASDAQ:VBIV)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017BMO Capital MarketsInitiated CoverageOutperform$11.00N/AView Rating Details
11/1/2017Canaccord GenuityInitiated CoverageBuy -> Buy$10.00N/AView Rating Details
7/31/2017Noble FinancialReiterated RatingBuyHighView Rating Details
10/10/2016LaidlawInitiated CoverageBuy$6.00N/AView Rating Details
7/26/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History for VBI Vaccines (NASDAQ:VBIV)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for VBI Vaccines (NASDAQ:VBIV)
Current Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Dividend History for VBI Vaccines (NASDAQ:VBIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VBI Vaccines (NASDAQ VBIV)

Insider Ownership Percentage: 34.10%
Institutional Ownership Percentage: 20.34%
Insider Trades by Quarter for VBI Vaccines (NASDAQ:VBIV)
Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Insider Trades by Quarter for VBI Vaccines (NASDAQ VBIV)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/30/2017Opko Health, Inc.Major ShareholderBuy655,738$3.05$2,000,000.90View SEC Filing  
10/30/2017Steven GillisDirectorBuy300,000$3.05$915,000.00View SEC Filing  
10/26/2017Life Sciences Maste PerceptiveMajor ShareholderBuy3,100,000$3.05$9,455,000.00View SEC Filing  
8/21/2017Francisco Diaz-MitomaInsiderBuy3,000$3.17$9,510.00View SEC Filing  
8/21/2017Jeff BaxterCEOBuy10,000$3.22$32,200.00View SEC Filing  
8/10/2017Jeff BaxterCEOBuy10,000$3.28$32,800.00View SEC Filing  
12/6/2016Perceptive Advisors LlcMajor ShareholderBuy3,383,955$3.05$10,321,062.75View SEC Filing  
8/14/2015Perceptive Advisors LlcMajor ShareholderBuy650,000$2.08$1,352,000.00View SEC Filing  
9/30/2013Murray George SmithCFOBuy3,027$1.13$3,420.51View SEC Filing  
8/21/2013Murray George SmithCFOBuy8,973$1.17$10,498.41View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for VBI Vaccines (NASDAQ VBIV)

Source:
DateHeadline
BMO Capital Markets Begins Coverage on VBI Vaccines, Inc. (VBIV)BMO Capital Markets Begins Coverage on VBI Vaccines, Inc. (VBIV)
www.americanbankingnews.com - November 19 at 6:56 PM
Benzingas Top Upgrades, Downgrades For November 15, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For November 15, 2017 - Benzinga
www.benzinga.com - November 16 at 5:24 AM
VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMOVBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO
finance.yahoo.com - November 16 at 5:24 AM
VBI Vaccines, Inc. (VBIV) Receives Consensus Rating of "Hold" from BrokeragesVBI Vaccines, Inc. (VBIV) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 15 at 10:12 AM
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
finance.yahoo.com - November 12 at 1:02 PM
VBI Vaccines Strengthens Board of Directors with Appointment of Ran NussbaumVBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum
finance.yahoo.com - November 2 at 10:52 AM
Opko Health, Inc. Purchases 655,738 Shares of VBI Vaccines, Inc. (VBIV) StockOpko Health, Inc. Purchases 655,738 Shares of VBI Vaccines, Inc. (VBIV) Stock
www.americanbankingnews.com - November 1 at 5:24 PM
Insider Buying: VBI Vaccines, Inc. (VBIV) Director Purchases 300,000 Shares of StockInsider Buying: VBI Vaccines, Inc. (VBIV) Director Purchases 300,000 Shares of Stock
www.americanbankingnews.com - October 31 at 8:26 PM
Head to Head Analysis: VBI Vaccines (VBIV) versus XOMA Corporation (XOMA)Head to Head Analysis: VBI Vaccines (VBIV) versus XOMA Corporation (XOMA)
www.americanbankingnews.com - October 31 at 1:06 PM
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common SharesVBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
finance.yahoo.com - October 31 at 11:41 AM
VBI Vaccines, Inc. (VBIV) Major Shareholder Acquires $9,455,000.00 in StockVBI Vaccines, Inc. (VBIV) Major Shareholder Acquires $9,455,000.00 in Stock
www.americanbankingnews.com - October 30 at 5:33 PM
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 MillionVBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million
finance.yahoo.com - October 30 at 8:14 AM
VBI Vaccines (VBIV) Prices Common Stock Offerings at $3.05/ShareVBI Vaccines (VBIV) Prices Common Stock Offerings at $3.05/Share
www.streetinsider.com - October 27 at 7:31 AM
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 MillionVBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million
finance.yahoo.com - October 26 at 12:04 PM
ETFs with exposure to VBI Vaccines, Inc. : October 26, 2017ETFs with exposure to VBI Vaccines, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 12:04 PM
VBI Vaccines (VBIV) Commences Concurrent Public Offering and Registered Direct Offering of Common SharesVBI Vaccines (VBIV) Commences Concurrent Public Offering and Registered Direct Offering of Common Shares
www.streetinsider.com - October 25 at 8:56 PM
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common SharesVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
www.marketwatch.com - October 25 at 8:56 PM
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common SharesVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
finance.yahoo.com - October 25 at 8:56 PM
VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017
finance.yahoo.com - October 17 at 8:43 AM
VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in BarcelonaVBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona
finance.yahoo.com - October 11 at 9:11 AM
Critical Analysis: Tetralogic Pharmaceuticals Corp (TLOG) and VBI Vaccines (VBIV)Critical Analysis: Tetralogic Pharmaceuticals Corp (TLOG) and VBI Vaccines (VBIV)
www.americanbankingnews.com - October 2 at 8:14 PM
VBI Vaccines to Present at September 2017 Investor ConferencesVBI Vaccines to Present at September 2017 Investor Conferences
finance.yahoo.com - September 12 at 11:46 AM
Reviewing VBI Vaccines (VBIV) & SIGA Technologies (SIGA)Reviewing VBI Vaccines (VBIV) & SIGA Technologies (SIGA)
www.americanbankingnews.com - September 5 at 10:22 AM
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical ProgramVBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
finance.yahoo.com - August 30 at 10:42 AM
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology SummitVBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
finance.yahoo.com - August 29 at 9:19 AM
ETFs with exposure to VBI Vaccines, Inc. : August 28, 2017ETFs with exposure to VBI Vaccines, Inc. : August 28, 2017
finance.yahoo.com - August 29 at 9:19 AM
VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:14 PM
VBI Vaccines, Inc. - (VBIV) CEO Jeff Baxter Purchases 10,000 SharesVBI Vaccines, Inc. - (VBIV) CEO Jeff Baxter Purchases 10,000 Shares
www.americanbankingnews.com - August 22 at 7:56 PM
ETFs with exposure to VBI Vaccines, Inc. : August 18, 2017ETFs with exposure to VBI Vaccines, Inc. : August 18, 2017
finance.yahoo.com - August 19 at 8:45 AM
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma MultiformeVBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
finance.yahoo.com - August 15 at 3:35 PM
Jeff Baxter Purchases 10,000 Shares of VBI Vaccines, Inc. (NASDAQ:VBIV) StockJeff Baxter Purchases 10,000 Shares of VBI Vaccines, Inc. (NASDAQ:VBIV) Stock
www.americanbankingnews.com - August 15 at 12:16 AM
VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q1, 2017 By the Numbers : August 7, 2017VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q1, 2017 By the Numbers : August 7, 2017
finance.yahoo.com - August 8 at 8:02 AM
VBI Vaccines, Inc. (VBIV) Receives Buy Rating from Noble FinancialVBI Vaccines, Inc. (VBIV) Receives Buy Rating from Noble Financial
www.americanbankingnews.com - July 31 at 9:40 AM
VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV VaccineVBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine
finance.yahoo.com - July 27 at 9:01 AM
VBI Vaccines, Inc. (VBIV) Short Interest Up 163.4% in JuneVBI Vaccines, Inc. (VBIV) Short Interest Up 163.4% in June
www.americanbankingnews.com - July 16 at 7:14 AM
VBI Vaccines (VBIV) CEO Jeff Baxter on Phase 3 Clinical Program for Sci-B-Vac Hepatitis B Vaccine Conference Call (Transcript)VBI Vaccines' (VBIV) CEO Jeff Baxter on Phase 3 Clinical Program for Sci-B-Vac Hepatitis B Vaccine Conference Call (Transcript)
seekingalpha.com - July 14 at 9:41 AM
VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B VaccineVBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine
finance.yahoo.com - July 12 at 8:53 AM
VBI Vaccines, Inc. (NASDAQ:VBIV) Receives Average Recommendation of "Buy" from BrokeragesVBI Vaccines, Inc. (NASDAQ:VBIV) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 12 at 8:50 AM
VBI Vaccines (VBIV) Announces Positive Outcome from Phase III Pre-IND Discussions with FDA for Hepatitis B Vaccine, Sci-B-VacVBI Vaccines (VBIV) Announces Positive Outcome from Phase III Pre-IND Discussions with FDA for Hepatitis B Vaccine, Sci-B-Vac
www.streetinsider.com - June 21 at 6:25 AM
Meet VBI Vaccines, The Biotech Up 100% In 2017Meet VBI Vaccines, The Biotech Up 100% In 2017
feeds.benzinga.com - March 7 at 1:36 PM
VBI Vaccines (VBIV) Announces Positive Response from Health Canadas Initial Evaluation of Sci-B-Vac Phase III Clinical ProgramVBI Vaccines (VBIV) Announces Positive Response from Health Canada's Initial Evaluation of Sci-B-Vac Phase III Clinical Program
www.streetinsider.com - February 23 at 3:06 AM
VBI VACCINES INCVBI VACCINES INC
www.finanznachrichten.de - February 23 at 3:06 AM
VBI Vaccines Receives Positive Response from Health Canadas Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical ProgramVBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program
us.rd.yahoo.com - February 22 at 10:46 AM
VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical StudyVBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study
us.rd.yahoo.com - February 7 at 3:49 PM
VBI Vaccines Closes $23.6 Million Financing from Perceptive AdvisorsVBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors
us.rd.yahoo.com - December 6 at 11:45 AM
8:42 am VBI Vaccines completes sale of 3.475 mln common shares at $3.05/share in a private placement to Perceptive Advisors, for total gross proceeds of approx. $10.6 mln; co also announced $13 mln in secured debt8:42 am VBI Vaccines completes sale of 3.475 mln common shares at $3.05/share in a private placement to Perceptive Advisors, for total gross proceeds of approx. $10.6 mln; co also announced $13 mln in secured debt
us.rd.yahoo.com - December 6 at 11:45 AM
Likely Clinton Victory Has Created an Opportunity for This StockLikely Clinton Victory Has Created an Opportunity for This Stock
www.thestreet.com - November 7 at 9:12 PM
VBI Vaccines (VBIV) Says Pre-IND Meeting with FDA Over VBI-1901 Complete; Fast-Track Designation Under ConsiderationVBI Vaccines (VBIV) Says Pre-IND Meeting with FDA Over VBI-1901 Complete; Fast-Track Designation Under Consideration
www.streetinsider.com - October 13 at 11:56 AM
Some of the Biotech Industrys Most Recognized Investors Are Focusing on the Zika VaccineSome of the Biotech Industry's Most Recognized Investors Are Focusing on the Zika Vaccine
www.huffingtonpost.com - October 13 at 11:56 AM
MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPTMSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT
www.rttnews.com - September 21 at 11:47 AM

Social Media

Financials

Financials are not available for this stock.

Chart

VBI Vaccines (NASDAQ VBIV) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.